A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis

Dermatology Online Journal

Volumn 15, Issue 2, 2009, Pages

  Kitamura, Gene ^a   Mehr, Neda ^a   Anderson, Nancy ^a   Sirichotiratana, Melissa ^a  

^a LOMA LINDA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE; CALCIPOTRIOL; CLOBETASOL; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; ISONIAZID; METHOTREXATE; TACROLIMUS; TAZAROTENE; TRIAMCINOLONE; ULOBETASOL PROPIONATE; UREA; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LIVER FUNCTION TEST; LOADING DRUG DOSE; MONOTHERAPY; PSORIATIC ARTHRITIS; PUSTULOSIS PALMOPLANTARIS; THORAX RADIOGRAPHY; TREATMENT RESPONSE; TUBERCULIN TEST; TUBERCULOSIS; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; DISEASE COURSE; DRUG COMBINATION; FOLLOW UP; HOSPITALIZATION; LETTER; MIDDLE AGED; PSORIASIS; RISK ASSESSMENT; TREATMENT FAILURE;

ANTIBODIES, MONOCLONAL; ANTITUBERCULAR AGENTS; ARTHRITIS, PSORIATIC; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; TUBERCULIN TEST; TUBERCULOSIS;

EID: 61849108219     PISSN: None     EISSN: 10872108     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Wolff K, Johnson RA, Suurmond Dick. Fitzpatrick's Color Atlas & Synopsis of Clinical Dermatology. 5th ed. McGraw-Hill, 2005.
2. Gordon KB, Ruderman EM. The treatment of psoriasis and psoriatic arthritis: an interdisciplinary approach. J Am Acad Dermatol. 2006; 54:S85-91. [PubMed]
3. Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJG, Chandler D , et al. British Association of Dermatologists. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol. 2005; 153:486-97. [PubMed]
4. Saraceno R, Chimenti S. How to manage infections in the era of biologics? Dermatol Ther. 2008; 21:180-186. [PubMed]
5. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arhtritis Rheum. 2004; 50:2264-72. [PubMed]
6. Gomez-Reino JJ, Carmona L, Descalzo A. Risk of Tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum. 2007; 57:756-61. [PubMed]
7. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet. 2000; 356:385-90. [PubMed]
8. Papp KA, Miller B, Gordon KB, Caro I, Kwon P, Compton PG, et al. Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol. 2006; 54:S164-70. [PubMed]
9. Carey W, Glazer S, Gottlieb AB, Lebwohl M, Leonardi C, Menter A, et al. Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol. 2006; 54:S171-81. [PubMed]
10. Papp KA, Ho V, Langley R, Lynde C, Poulin Y, Shear N, et al. Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis. J Cutan Med Surg. 2006; 9: 26-32. [PubMed]
11. Bang B, Gniadecki R. Severe exacerbation of psoriatic arthritis during treatment with efalizumab. A case report. Acta Derm Venereol 2006; 86:456-7. [PubMed]
12. Gottlieb AB, Matheson RT, Lowe, N, Krueger GG, Kang S, Goffe BS, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003; 139:1627-32. [PubMed]
13. Adisen E, Karaca F, Gürer MA. When there is no single best biological agent: psoriasis and psoriatic arthritis in the same patient responding to different biological agents. Clin Exp Dermatol. 2008; 33:164-6. [PubMed]
14. Menter A, Hamilton TK, Toth DP, Leung HM, Wetherill G, Hennessey B, et al. Transitioning patients from efalizumab to alternative psoriasis therapies: finding from an open-label, multicenter, phase IIIb study. Int J Dermatol 2007; 46:637-48. [PubMed]
15. Papp K. The safety of etanercept for the treatment of plaque psoriasis. Ther Clin Risk Manag. 2007; 3:245-258. [PubMed]
16. Hernandez C, Cetner AS, Jordan JE, Puangsuvan SN, Robinson JK. Tuberculosis in the age of biologic therapy. J Am Acad Dermatol. 2008; 59:363-80. [PubMed]